80.
(b) Share-based compensation expense.
(c) Transaction and integration costs of $16,736 plus change in fair value of contingent consideration of $200.
(d) Interest associated with debt discount and debt issuance costs and, to a small extent, liability under a 2007 government litigation settlement.
(e) Revenue related to upfront and milestone payments. JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (In thousands, except per share amounts) (Unaudited) Three Months Ended June 30,Six Months Ended June 30,2012201120122011 GAAP net income$ 27,145$ 33,202$
54,826$ 55,029 Intangible asset amortization
15,7511,86229,2643,724 Share-based compensation expense
5,2583,4158,5396,563 Purchase accounting inventory fair value step-up
4,011-6,380- Transaction and integration costs
10,641-16,736- Change in fair value of contingent consideration
200-200- Other non-cash expense (income)
267(96)309(175) Income tax adjustments
2,897-2,897- Adjusted net income$ 66,170$ 38,383$ 119,151$ 65,141 GAAP net income per diluted share
$
.45$
.71$
.92$
.19 Adjusted net income per diluted share
$
.09$
.82$
2.01$
.41 Shares used in computing GAAP and adjusted net income per diluted share amounts
60,55446,60159,31946,238 JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP 2012 FINANCIAL GUIDANCE (In millions, except per share amounts) GAAP net income
$139 - $154 Intangible asset amortization
70 Share-based compensation expense
25 - 26 Purchase accounting inventory fair value step-up
'/>"/>SOURCE Jazz Pharmaceuticals plc Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1.
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 20122.
Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference3.
Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement4.
BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals5.
Icahn Issues Statement Regarding Amylin Pharmaceuticals6.
Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan7.
Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study8.
Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma9.
Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 201210.
Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer11.
Avanir Pharmaceuticals To Present at Three Conferences In May